TABLE 1.
Escherichia coli antibiotic resistance among VA inpatient and outpatient facilities nationally, by method used to describe rates (2009 to 2013)
| Antibiotic categorya | % nonsusceptible (no. of isolates tested) |
||
|---|---|---|---|
| First isolate per patient per facility per month (n = 297,046)b | First isolate per patient per facility per year (n = 244,411)c | Most resistant isolate per patient per facility per year (n = 244,411) | |
| Aminoglycoside | 12.6 (296,022) | 10.9 (243,577) | 11.5 (243,590) |
| Antipseudomonal penicillin/β-lactamase inhibitor | 5.3 (206,707) | 4.7 (170,013) | 5.5 (170,342) |
| Carbapenem | 0.4 (231,153) | 0.4 (189,809) | 0.4 (190,017) |
| Extended-spectrum cephalosporin | 6.9 (264,519) | 6.0 (217,513) | 6.5 (217,886) |
| Fluoroquinolone | 34.3 (291,674) | 29.5 (240,005) | 30.4 (240,086) |
| Nitrofurantoin | 6.2 (249,096) | 5.4 (204,526) | 6.1 (204,611) |
| Amoxicillin or ampicillin/β-lactamase inhibitor | 39.6 (238,738) | 37.2 (196,203) | 39.0 (196,450) |
| Trimethoprim-sulfamethoxazole | 28.2 (296,501) | 25.2 (243,957) | 26.3 (243,982) |
The aminoglycoside category included amikacin, gentamicin, and tobramycin. The antipseudomonal penicillin/β-lactamase inhibitor category included piperacillin-tazobactam and ticarcillin-clavulanic acid. The carbapenem category included imipenem, meropenem, doripenem, and ertapenem. The extended-spectrum cephalosporin category included ceftriaxone, ceftazidime, cefotaxime, and cefepime. The fluoroquinolone category included levofloxacin and ciprofloxacin. The amoxicillin or ampicillin/β-lactamase inhibitor category included amoxicillin-clavulanic acid and ampicillin-sulbactam.
National Healthcare Safety Network method.
Clinical and Laboratory Standards Institute method.